Hyperbilirubinemiarepresents a spectrum of clinical syndromes characterized by elevated bilirubin levels in the bloodstream, reflecting diverse underlying hepatic, hemolytic, or metabolic disorders. This expanded study evaluates the clinical forms and management strategiesfor hyperbilirubinemia in a diverse cohort of 200 patients, segmented into physiological, pathological, hemolytic, and obstructive categories. Advanced laboratory diagnostics, imaging techniques, and therapeutic interventions including phototherapy, pharmacotherapy, and surgical approaches were analyzed. The research demonstrates how specific patterns of bilirubin metabolism correlate with disease severity, helping clinicians optimize care pathways. Emphasis is placed on early detection, etiological classification, and integrated therapeutic planning to prevent bilirubin-induced complications such as kernicterus and hepatic failure.
Hyperbilirubinemiarepresents a spectrum of clinical syndromes characterized by elevated bilirubin levels in the bloodstream, reflecting diverse underlying hepatic, hemolytic, or metabolic disorders. This expanded study evaluates the clinical forms and management strategiesfor hyperbilirubinemia in a diverse cohort of 200 patients, segmented into physiological, pathological, hemolytic, and obstructive categories. Advanced laboratory diagnostics, imaging techniques, and therapeutic interventions including phototherapy, pharmacotherapy, and surgical approaches were analyzed. The research demonstrates how specific patterns of bilirubin metabolism correlate with disease severity, helping clinicians optimize care pathways. Emphasis is placed on early detection, etiological classification, and integrated therapeutic planning to prevent bilirubin-induced complications such as kernicterus and hepatic failure.
| № | Author name | position | Name of organisation |
|---|---|---|---|
| 1 | Abdullayev M.X. | ! | Tashkent Medical Academy, Termiz Branch |
| 2 | Bekmirzayeva G.E. | ! | Tashkent Medical Academy, Termiz Branch |
| № | Name of reference |
|---|---|
| 1 | Maisels MJ, Bhutani VK, Bogen D, et al. Hyperbilirubinemia in the newborn infant ≥35 weeks' gestation: an update. Pediatrics. 2009;124(4):1193–1198.2.Kaplan M, Hammerman C. Bilirubin and neurotoxicity. Semin Fetal Neonatal Med. 2002;7(2):135–146.3.Fischer JE, Bland KI, Callery MP. Mastery of Surgery. Lippincott Williams & Wilkins; 2012. Kliegman R, Stanton B, St Geme J, SchorN. Nelson Textbook of Pediatrics. 21st ed. Elsevier; 2020.5.Ahn YH, Choi YH, et al. Clinical management and outcome of neonatal cholestasis in Korea. Pediatr Gastroenterol Hepatol Nutr. 2018;21(3):182–189.6.Lee JY, Kim MJ. Diagnostic approach to cholestaticjaundice in children. Clin Exp Hepatol. 2019;5(1):9–15.7.Watchko JF. Hemolytic disease of the newborn. N Engl J Med. 2014;370:125–135. |